Roche and My­lan set­tle a scrap over Her­ceptin, clear­ing path to a glob­al launch of a knock­off drug

Two weeks ago Roche shares jumped on the news that the phar­ma gi­ant had scored win­ning Phase III da­ta sup­port­ing the com­bi­na­tion of Her­ceptin and Per­je­ta in fight­ing ear­ly-stage breast can­cer. And to­day, Roche and My­lan are an­nounc­ing that they’ve agreed to a set­tle­ment of their long-run­ning dis­pute over a biosim­i­lar of Her­ceptin, leav­ing My­lan with boast­ing rights for its shot at be­com­ing the first com­pa­ny to get a knock­off on­to the US mar­ket.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.